SPOTLIGHT -
Dr. Gold on Leveraging Sotorasib in KRAS G12C–Mutated NSCLC
Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.
Read More
Dr. Gold on the Future of Osimertinib in Lung Cancer
Kathryn A. Gold, MD, associate professor of medicine, University of California, San Diego, discusses the future of osimertinib (Tagrisso) in the treatment of patients with EGFR-mutant lung cancer.
Dr. Gold on Defining Head and Neck Squamous Cell Carcinoma
Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, differentiates carcinogen-induced and virally associated head and neck squamous cell carcinoma.
Dr. Gold on Approaching Patients with HPV-Positive Head and Neck Cancer
Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses approaching patients with HPV-positive head and neck cancer.
Dr. Gold on the Current State of HPV-Related Head and Neck Cancer
Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses the current state of human papilloma virus (HPV)-related head and neck cancer.
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
Dr Westin on Outcomes of the SOLAR Trial in RAS-Mutant Gynecological Malignances